Vavricka John (CIK 1829630) reported 5 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-02-03). Recent activity: Buy AVIR (42,083 shares), Sell AVIR (11,570 shares), Buy AVIR (33,333 shares), Buy AVIR (8,750 shares), Sell AVIR (11,517 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-03 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Commercial Officer | Buy | 42,083 | $0 |
| 2026-02-03 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Commercial Officer | Sell | 11,570 | $49,057 |
| 2025-02-04 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Commercial Officer | Buy | 33,333 | $0 |
| 2025-02-04 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Commercial Officer | Buy | 8,750 | $0 |
| 2025-02-04 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Commercial Officer | Sell | 11,517 | $35,242 |
Source: SEC Form 4 filings · as of 2026-02-03